SynthesisDigestive diseases and sciences2016
Reduced Risk of Barrett's Esophagus in Statin Users: Case-Control Study and Meta-Analysis.
Synthesis in Digestive diseases and sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 5 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- A Systematic Review and Meta-analysis of the Relationship between Statin Intake and Esophageal Cancer.Anti-cancer agents in medicinal chemistry · 2024Pooled it
- Lifestyle interventions can reduce the risk of Barrett's esophagus: a systematic review and meta-analysis of 62 studies involving 250,157 participants.Cancer medicine · 2021Pooled it
- The relationship between metabolic syndrome and increased risk of Barrett's esophagus: an updated systematic review and meta-analysis.BMC gastroenterology · 2020Pooled it
- Systematic Review and Meta-analysis: Use of Statins Is Associated with a Reduced Incidence of Oesophageal Adenocarcinoma.Journal of gastrointestinal cancer · 2018Pooled it
- Statins and gastroesophageal reflux disease: A meta-analysis.Journal of postgraduate medicinePooled it
- Carcinoma of Esophagus.Journal of gastroenterology and hepatology · 2025Review
- Role of Obesity, Physical Exercise, Adipose Tissue-Skeletal Muscle Crosstalk and Molecular Advances in Barrett's Esophagus and Esophageal Adenocarcinoma.International journal of molecular sciences · 2022Review
- Statins as Potential Therapeutics for Esophageal Cancer.Journal of gastrointestinal cancer · 2021Review
- Leptin activates Akt in oesophageal cancer cells via multiple atorvastatin-sensitive small GTPases.Molecular and cellular biochemistry · 2021Article
- Global burden and epidemiology of Barrett oesophagus and oesophageal cancer.Nature reviews. Gastroenterology & hepatology · 2021Review
- Review
- Chronic High-Fat Diet Induces Early Barrett's Esophagus in Mice through Lipidome Remodeling.Biomolecules · 2020Article
- Interactive decision support for esophageal adenocarcinoma screening and surveillance.BMC gastroenterology · 2019Article
- Risk of histologic Barrett's esophagus between African Americans and non-Hispanic whites: A meta-analysis.United European gastroenterology journal · 2018Article
- Do Statins Increase the Risk of Esophageal Conditions? Findings from Four Propensity Score-Matched Analyses.Clinical drug investigation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUse of statins has been associated with a reduced incidence of esophageal adenocarcinoma in population-based studies. However there are few studies examining statin use and the development of Barrett's esophagus.
aimThe purpose of this study was to examine the association between statin use and the presence of Barrett's esophagus in patients having their first gastroscopy.
methodsWe have performed a case-control study comparing statin use between patients with, and without, an incident diagnosis of non-dysplastic Barrett's esophagus. Male Barrett's cases (134) were compared to 268 male age-matched controls in each of two control groups (erosive gastro-esophageal reflux and dyspepsia without significant upper gastrointestinal disease). Risk factor and drug exposure were established using standardised interviews. Logistic regression was used to compare statin exposure and correct for confounding factors. We performed a meta-analysis pooling our results with three other case-control studies.
resultsRegular statin use was associated with a significantly lower incidence of Barrett's esophagus compared to the combined control groups [adjusted OR 0.62 (95 % confidence intervals 0.37-0.93)]. This effect was more marked in combined statin plus aspirin users [adjusted OR 0.43 (95 % CI 0.21-0.89)]. The inverse association between statin or statin plus aspirin use and risk of Barrett's was significantly greater with longer duration of use. Meta-analysis of pooled data (1098 Barrett's, 2085 controls) showed that statin use was significantly associated with a reduced risk of Barrett's esophagus [pooled adjusted OR 0.63 (95 % CI 0.51-0.77)].
conclusionsStatin use is associated with a reduced incidence of a new diagnosis of Barrett's esophagus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.